Condition: Preeclampsia (PE) · Fetal Growth Restriction · Congenital Abnormalities · Sponsor: Institute of Health Information and Statistics of the Czech Republic
The project is a national, prospective, multicenter pilot project. The project is focus on setting up the combined first trimester screening in the Czech Republic. The combined first trimester screening is aimed at predicting and detecting the most serious obstetric complications, such as the great obstetrical syndromes (preeclampsia, fetal growth restriction, preterm labor and intrauterine fetal demise "IUFD") and structural congenital defects (morphological and chromosomal). The primary objective of the project is to create a unified methodology for performing and evaluating the combined first trimester screening in connection with the National Health Information System (hereinafter referred to as "NHIS"), which will enable recording, providing analysis and linking recorded clinical parameters with data in the NHIS. The pilot project will also provide data for modeling appropriate mechanisms for reimbursement from public health insurance.
This description comes directly from the study's public registry record.
Petra Brlica Heideová, Msc. · +420 770 171 533 · Petra.BrlicaHeideova@uzis.cz
Lucie Mandelová, PhD · +420 770 190 828 · lucie.mandelova@uzis.cz
Always discuss trial participation with your own doctor first.
| Regional Health Corpotarion - Most Hospital | Most, Czechia, Czechia | Recruiting |
| University Hospital Olomouc | Olomouc, Czechia, Czechia | Recruiting |
| Institute for the Care of Mother and Child | Prague, Czechia, Czechia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07015203